- Home
- ODD vs ARQT Comparison
ODD vs ARQT Comparison
Compare ODD & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | ARQT |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ODD | ARQT |
|---|---|---|
| Price | $42.18 | $28.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $69.45 | $24.83 |
| AVG Volume (30 Days) | 689.5K | ★ 1.8M |
| Earning Date | 11-19-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.01 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $780,758,000.00 | $317,929,000.00 |
| Revenue This Year | $26.15 | $85.51 |
| Revenue Next Year | $20.55 | $30.74 |
| P/E Ratio | $23.40 | ★ N/A |
| Revenue Growth | 25.80 | ★ 129.21 |
| 52 Week Low | $35.30 | $11.13 |
| 52 Week High | $79.18 | $31.77 |
Technical Indicators
Market Signals| Indicator | ODD | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 53.65 |
| Support Level | $41.36 | $27.55 |
| Resistance Level | $44.09 | $30.26 |
| Average True Range (ATR) | 1.63 | 1.03 |
| MACD | -0.02 | -0.28 |
| Stochastic Oscillator | 16.56 | 35.15 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.